VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The efficacy of ruxolitinib re-treatment in patients with MF

Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, shares some insights into the safety and efficacy of re-treating patients with ruxolitinib as an alternative treatment approach in myelofibrosis (MF). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter